ARIO PHARMA LIMITED

STATEMENT OF COMPLIANCE



.D1 07/06/2018 COMPANIES HOUSE

#42

Dated:

5 June

2018

We, the undersigned (being all of the directors of the above mentioned company (the "Company") as at the date of this statement) confirm for the purposes of section 644(5) Companies Act 2006 that:

- the solvency statement attached in Appendix A of this statement (the "Solvency Statement") was made not more than 15 days prior to the passing of a special resolution dated 5 June 2018 (a copy of which is attached in Appendix B of this statement (the "Special Resolution")); and
- a copy of the Solvency Statement was provided to each eligible member of the Company in accordance with section 642(2) Companies Act 2006.

This statement may be executed in several counterparts (whether original or facsimile counterparts) and upon due execution of all such counterparts by one or more parties, each counterpart shall be deemed to be an original hereof. The exchange of a fully executed version of this statement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this statement and no exchange of originals is necessary.

This statement and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual claims) shall be governed by and construed in accordance with English law and the English courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this statement, its substance or formation

Signed:	KETTH MCCULLAGH	Signed:	JOHN FORD
Signed:	GEERT-JAN MULDER	Signed:	ALAN O'CONNELL
Signed:		Signed:	
	HIIGO SI COTWEG		SOMUSIERRAMANIAM

ARIO PHARMA LIMITED

STATEMENT OF COMPLIANCE

Dated: 5 June 2018

We, the undersigned (being all of the directors of the above mentioned company (the "Company") as at the date of this statement) confirm for the purposes of section 644(5) Companies Act 2006 that:

- the solvency statement attached in Appendix A of this statement (the "Solvency Statement") was made not more than 15 days prior to the passing of a special resolution dated 5 June 2018 (a copy of which is attached in Appendix B of this statement (the "Special Resolution")); and
- a copy of the Solvency Statement was provided to each eligible member of the Company in accordance with section 642(2) Companies Act 2006.

This statement may be executed in several counterparts (whether original or facsimile counterparts) and upon due execution of all such counterparts by one or more parties, each counterpart shall be deemed to be an original hereof. The exchange of a fully executed version of this statement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this statement and no exchange of originals is necessary.

This statement and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual claims) shall be governed by and construed in accordance with English law and the English courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this statement, its substance or formation.

Signed:		Signed:	
	KEITH MCCULLAGH		JOHN FORD
Signed:	FAMIR.	Signed:	
	GEERT-JAN MULDER		ALAN O'CONNELL
Signed:	Mon	Signed:	
	HUGO SLOOTWEG		SOMIL SURRAMANIAM

ARIO PHARMA LIMITED

STATEMENT OF COMPLIANCE

Dated:

5 June

2018

We, the undersigned (being all of the directors of the above mentioned company (the "Company") as at the date of this statement) confirm for the purposes of section 644(5) Companies Act 2006 that:

- the solvency statement attached in Appendix A of this statement (the "Solvency Statement") was made not more than 15 days prior to the passing of a special resolution dated 5 June 2018 (a copy of which is attached in Appendix B of this statement (the "Special Resolution")); and
- a copy of the Solvency Statement was provided to each eligible member of the Company in accordance with section 642(2) Companies Act 2006.

This statement may be executed in several counterparts (whether original or facsimile counterparts) and upon due execution of all such counterparts by one or more parties, each counterpart shall be deemed to be an original hereof. The exchange of a fully executed version of this statement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this statement and no exchange of originals is necessary.

This statement and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual claims) shall be governed by and construed in accordance with English law and the English courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this statement, its substance or formation.

Signed:	KEITH MCCULLAGH	Signed:	JOHN FORD
Signed:	GEERT-JAN MULDER	Signed:	ALAN O'CONNELL
Signed:	HUGO SLOOTWEG	Signed:	SOMU SUBRAMANIAM

ARIO PHARMA LIMITED

STATEMENT OF COMPLIANCE

Dated: 5 June 2018

We, the undersigned (being all of the directors of the above mentioned company (the "Company") as at the date of this statement) confirm for the purposes of section 644(5) Companies Act 2006 that:

- the solvency statement attached in Appendix A of this statement (the "Solvency Statement") was made not more than 15 days prior to the passing of a special resolution dated 5 June 2018 (a copy of which is attached in Appendix B of this statement (the "Special Resolution")); and
- 2. a copy of the Solvency Statement was provided to each eligible member of the Company in accordance with section 642(2) Companies Act 2006.

This statement may be executed in several counterparts (whether original or facsimile counterparts) and upon due execution of all such counterparts by one or more parties, each counterpart shall be deemed to be an original hereof. The exchange of a fully executed version of this statement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this statement and no exchange of originals is necessary.

This statement and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual claims) shall be governed by and construed in accordance with English law and the English courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this statement, its substance or formation.

Signed:		Signed:	
	KEITH MCCULLAGH		JOHN FORD
Signed:	GEÉRT-JÁN MŰLDÉR	Signed:	ALAN O CONNELL ON-M
Signed:		Signed:	
	HUGO SLOOTWEG		SOMU SUBRAMANIAM

ARIO PHARMA LIMITED

STATEMENT OF COMPLIANCE

Dated:

5 June

2018

We, the undersigned (being all of the directors of the above mentioned company (the "Company") as at the data of this statement) confirm for the purposes of section 644(5) Companies Act 2006 that:

- the solvency statement attached in Appendix A of this statement (the "Solvency Statement") was made not more than 15 days prior to the passing of a special resolution dated 5 June 2018 (a copy of which is attached in Appendix B of this statement (the "Special Resolution")); and
- a copy of the Solvency Statement was provided to each eligible member of the Company in accordance with section 642(2) Companies Act 2006.

This statement may be executed in several counterparts (whether original or facsimile counterparts) and upon due execution of all such counterparts by one or more parties, each counterpart shall be deemed to be an original hereof. The exchange of a fully executed version of this statement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this statement and no exchange of originals is necessary.

This statement and any dispute or claim arising out of or in connection with its subject matter or formation (including noncontractual claims) shall be governed by and construed in accordance with English is wand the English courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this statement, its substance or formation.

Signed:		Signed:	
	KEITH MCCULLAGH	JOHN FORD	
Signed:		Signed:	
	GEERT-JAN MULDER	ALAN O'CONNELL	
Signed:		Signed:	
	HUGO SLOOTWEG	SOMU SUBRAMANIAM	